Prevention of Lyme Borreliosis

Lyme Borreliosis in Europe and North America: Epidemiology and Clinical Practice

Volumn , Issue , 2011, Pages 225-244

  Sood, Sunil K ^a,b  

^a Northwell Health   (United States)

^b Donald and Barbara Zucker School of Medicine at Hofstra Northwell   (United States)

Author keywords

Lyme borreliosis prevention, an emerging infectious disease in the Old and New worlds; Lyme disease prevention, by immunization tick bite risk reduction, and vaccines for prevention; Tick control, investigations decreasing spirochetal burden in nature, and tick control in nature

Indexed keywords

EID: 84886579545     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470933961.ch12     Document Type: Chapter

References (107)

1. AAP: Lyme disease. In Pickering LK, Baker CJ, Kimberlin DW, Long SSE (eds): Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL, American Academy of Pediatrics; 2009.
2. Abbott A: Lyme disease. Uphill struggle. Nature 439:524-525; 2006.
3. Agre F, Schwartz R: The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child 147:945-947; 1993.
4. Anderson JF: Mammalian and avian reservoirs for Borrelia burgdorferi. Ann NY Acad Sci 539:180-191; 1988.
5. Anon: Lyme disease vaccine. Med Lett Drugs Ther 41:29-30; 1999.
6. Anon: When a vaccine is safe. Nature 439:509; 2006.
7. Beran J, De Clercq N, Dieussaert I, van Hoecke C: Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old. Clin Infect Dis 31:1504-1507; 2000.
8. Brown EL, Kim JH, ReisenbichlerES, HookM: Multicomponent Lyme vaccine. Three is not a crowd. Vaccine 23:3687-3696; 2005.
9. Burgdorfer W: Vector/host relationships of the Lyme disease spirochete, Borrelia burgdorferi. Rheum Dis Clin North Am 15:775-787; 1989.
10. Carroll JF, Klun JA, Debboun M: Repellency of deet and SS220 applied to skin involves olfactory sensing by two species of ticks. Med Vet Entomol 19:101-106; 2005.
11. CDC: Lyme disease. United States, 1980. MMWR Morb Mortal Wkly Rep 30:489-482, 497; 1981.
12. Chou JT, Rossignol PA, Ayres JW: Evaluation of commercial insect repellents on human skin against Aedes aegypti (Diptera: Culicidae). J Med Entomol 34:624-630; 1997.
13. Cooper JD, Feder HM Jr: Inaccurate information about Lyme disease on the internet. Pediatr Infect Dis J 23:1105-1108; 2004.
14. Costello CM, Steere AC, Pinkerton RE, Feder HM Jr: A prospective study of tick bites in an endemic area for Lyme disease. Conn Med 53:338-340; 1989.
15. Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E: The public health impact of Lyme disease in Maryland. J Infect Dis 173:1260-1262; 1996.
16. Crippa M, Rais O, Gern L: Investigations on the mode and dynamics of transmission and infectivity of Borrelia burgdorferi sensu stricto and Borrelia afzelii in Ixodes ricinus ticks. Vector Borne Zoonotic Dis 2:3-9; 2002.
17. Curran KL, Fish D: Increased risk of Lyme disease for cat owners. N Engl J Med 320:183; 1989.
18. Curran KL, Fish D, Piesman J: Reduction of nymphal Ixodes dammini (Acari: Ixodidae) in a residential suburban landscape by area application of insecticides. J Med Entomol 30:107-113; 1993.
19. Daltroy LH, Phillips C, Lew R, Wright E, Shadick NA, Liang MH: A controlled trial of a novel primary prevention program for Lyme disease and other tick-borne illnesses. Health Educ Behav 34:531-542; 2007.
20. De la Fuente J, Kocan KM, Almazan C, Blouin EF: Targeting the tick-pathogen interface for novel control strategies. Front Biosci 13:6947-6956; 2008.
21. Ding W, Huang X, Yang X, Dunn JJ, Luft BJ, Koide S, Lawson CL: Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol 302:1153-1164; 2000.
22. Dolan MC, Maupin GO, Schneider BS, Denatale C, Hamon N, Cole C, Zeidner NS, Stafford KC III: Control of immature Ixodes scapularis (Acari: Ixodidae) on rodent reservoirs of Borrelia burgdorferi in a residential community of southeastern Connecticut. J Med Entomol 41:1043-1054; 2004.
23. Dolan MC, Zeidner NS, Gabitzsch E, Dietrich G, Borchert JN, Poche RM, Piesman J: A doxycycline hyclate rodent bait formulation for prophylaxis and treatment of tick-transmitted Borrelia burg-dorferi. Am J Trop Med Hyg 78:803-805; 2008.
24. Dolan MC, Jordan RA, Schulze TL, Schulze CJ, Manning MC, Ruffolo D, Schmidt JP, Piesman J, Karchesy JJ: Ability of two natural products, nootkatone and carvacrol, to suppress Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae) in a Lyme disease endemic area of New Jersey. J Econ Entomol 102:2316-2324; 2009.
25. Earnhart CG, Marconi RT: An octavalent Lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccin 3:281-289; 2007.
26. Earnhart CG, Buckles EL, Marconi RT: Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 25:466-480; 2007.
27. Evans G: Update on vaccine liability in the United States. Presentation at the National Vaccine Program Office Workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002. Clin Infect Dis 42(suppl 3): S130-S137; 2006.
28. Falco RC, Fish D, Piesman J: Duration of tick bites in a Lyme disease-endemic area. Am J Epidemiol 143:187-192; 1996.
29. Feder HM Jr, Beran J, van Hoecke C, Abraham B, De Clercq N, Buscarino C, Parenti DL: Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. J Pediatr 135:575-579; 1999.
30. Fikrig E, Barthold SW, Kantor FS, Flavell RA: Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250:553-556; 1990.
31. Fingerle V, Rauser S, Hammer B, Kahl O, Heimerl C, Schulte-Spechtel U, Gern L, Wilske B: Dynamics of dissemination and outer surface protein expression of different European Borrelia burgdorferi sensu lato strains in artificially infected Ixodes ricinus nymphs. J Clin Microbiol 40:1456-1463; 2002.
32. Fradin MS, Day JF: Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 347:13-18; 2002.
33. Gomes-Solecki MJ, Brisson DR, Dattwyler RJ: Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine 24:4440-4449; 2006.
34. Goodyer L, Behrens RH: Short report. The safety and toxicity of insect repellents. Am J Trop Med Hyg 59:323-324; 1998.
35. Gray J, Kahl O, Lane RS, Stanek G: Lyme Borreliosis. Biology, Epidemiology and Control. New York, CAB International; 2002.
36. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, Field JA, Steere AC, Huber BT: Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703-706; 1998.
37. Hagman KE, Yang X, Wikel SK, Schoeler GB, Caimano MJ, Radolf JD, Norgard MV: Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect Immun 68:4759-4764; 2000.
38. Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND: Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infect Immun 68:6457-6460; 2000.
39. Hayes EB, Maupin GO, Mount GA, Piesman J: Assessing the prevention effectiveness of local Lyme disease control. J Public Health Manag Pract 5:84-92; 1999.
40. Hayes EB, Piesman J: How can we prevent Lyme disease? N Engl J Med 348:2424-2430; 2003.
41. Herrington JE Jr, Campbell GL, Bailey RE, Cartter ML, Adams M, Frazier EL, Damrow TA, Gensheimer KF: Predisposing factors for individuals' Lyme disease prevention practices: Connecticut, Maine, and Montana. Am J Public Health 87:2035-2038; 1997.
42. Hildebrandt A, Schmidt KH, Wilske B, Dorn W, Straube E, Fingerle V: Prevalence of four species of Borrelia burgdorferi sensu lato and coinfection with Anaplasma phagocytophila in Ixodes ricinus ticks in central Germany. Eur J Clin Microbiol Infect Dis 22:364-367; 2003.
43. Jaenson TG, Palsson K, Borg-Karlson AK: Evaluation of extracts and oils of tick-repellent plants from Sweden. Med Vet Entomol 19:345-352; 2005.
44. Jouda F, Perret JL, Gern L: Density of questing Ixodes ricinus nymphs and adults infected by Borrelia burgdorferi sensu lato in Switzerland. Spatio-temporal pattern at a regional scale. Vector Borne Zoonotic Dis 4:23-32; 2004.
45. Katz TM, Miller JH, Hebert AA: Insect repellents. Historical perspectives and new developments. J Am Acad Dermatol 58:865-871; 2008.
46. Koren G, Matsui D, Bailey B: DEET-based insect repellents Safety implications for children and pregnant and lactating women. CMAJ 169:209-212; 2003.
47. Korenberg EI, Vorobyeva NN, Moskvitina HG, Gorban L: Prevention of borreliosis in persons bitten by infected ticks. Infection 24:187-189; 1996.
48. Labuda M, Trimnell AR, LickovaM, KazimirovaM, Davies GM, Lissina O, Hails RS, Nuttall PA: An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog 2:e27; 2006.
49. Lathrop SL, Ball R, Haber P, Mootrey GT, Braun MM, Shadomy SV, Ellenberg SS, Chen RT, Hayes EB: Adverse event reports following vaccination for Lyme disease. December 1998-July 2000. Vaccine 20:1603-1608; 2002.
50. Livey I, O'Rourke M, Traweger A, Savidis-Dacho H, Crowe BA, Barrett PN, Yang X, Dunn JJ, Luft BJ: A new approach to a Lyme disease vaccine. Clin Infect Dis 52(Suppl 3):s266-270; 2011.
51. Luft BJ, Dunn JJ, Lawson CL: Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J Infect Dis 185(suppl 1): S46-S51; 2002.
52. Madurawe RD, Chase TE, Tsao EI, Bentley WE: A recombinant lipoprotein antigen against Lyme disease expressed in E. coli. Fermentor operating strategies for improved yield. Biotechnol Prog 16:571-576; 2000.
53. Maiwald M, Oehme R, March O, Petney TN, Kimmig P, Naser K, Zappe HA, Hassler D, Von Knebel Doeberitz M: Transmission risk of Borrelia burgdorferi sensu lato from Ixodes ricinus ticks to humans in southwest Germany. Epidemiol Infect 121:103-108; 1998.
54. Malouin R, Winch P, Leontsini E, Glass G, Simon D, Hayes EB, Schwartz BS: Longitudinal evaluation of an educational intervention for preventing tick bites in an area with endemic lyme disease in Baltimore County, Maryland. Am J Epidemiol 157:1039-1051; 2003.
55. Matuschka FR, Spielman A: Risk of infection from and treatment of tick bite. Lancet 342:529-530; 1993.
56. McSweegan E: Lyme vaccine demonized by advocacy groups. Nature 440:278; 2006.
57. McSweegan E: The Lyme vaccine. A cautionary tale. Epidemiol Infect 135:9-10; 2007.
58. Meek JI, Roberts CL, Smith EV Jr, Cartter ML: Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract 2:61-65; 1996.
59. Meiners T, Hammer B, Gobel UB, KahlO: Determining the tick scutal index allows assessment of tick feeding duration and estimation of infection risk with Borrelia burgdorferi sensu lato in a person bitten by an Ixodes ricinus nymph. Int J Med Microbiol 296(suppl 40): 103-107; 2006.
60. Meltzer MI, Dennis DT, Orloski KA: The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 5:321-328; 1999.
61. Montemarano AD, Gupta RK, Burge JR, Klein K: Insect repellents and the efficacy of sunscreens. Lancet 349:1670-1671; 1997.
62. Murray T, Feder HM Jr: Management of tick bites and early Lyme disease. A survey of Connecticut physicians. Pediatrics 108:1367-1370; 2001.
63. Nadelman R, Wormser GP: Single-dose doxycycline for the prevention of Lyme disease. N Engl J Med 345:1348-1350; 2001.
64. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, Welch P, Marcus R, Aguero-Rosenfeld ME, Dennis DT, Wormser GP: Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 345:79-84; 2001.
65. Needham GR: Evaluation of five popular methods for tick removal. Pediatrics 75:997-1002; 1985.
66. NIAID: Lyme Disease: Vaccine Production [Online]; 2007. Available: http://www3.niaid.nih.gov/topics/lymeDisease/research/vaccine.htm [Accessed January 27, 2011].
67. Paul H, Gerth HJ, Ackermann R: Infectiousness for humans of Ixodes ricinus containing Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg [A] 263:473-476; 1987.
68. Peavey CA, Lane RS: Transmission of Borrelia burgdorferi by Ixodes pacificus nymphs and reservoir competence of deer mice (Peromyscus maniculatus) infected by tick-bite. J Parasitol 81:175-178; 1995.
69. Phillips CB, Liang MH, Sangha O, Wright EA, Fossel AH, Lew RA, Fossel KK, Shadick NA: Lyme disease and preventive behaviors in residents of Nantucket Island, Massachusetts. Am J Prev Med 20:219-224; 2001.
70. Piesman J: Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks. J Infect Dis 167:1082-1085; 1993.
71. Piesman J: Strategies for reducing the risk of Lyme borreliosis in North America. Int J Med Microbiol 296(suppl 40): 17-22; 2006.
72. Piesman J, Dolan MC: Protection against lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 39:509-512; 2002.
73. Piesman J, Eisen L: Prevention of tick-borne diseases. Annu Rev Entomol 53:323-543; 2008.
74. Plotkin SA: Correcting a public health fiasco: The need for a new vaccine against Lyme disease. Clin Infect Dis 52(Suppl 3):s271-275; 2011.
75. Poland GA: Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis 52(Suppl 3):s253-258; 2011.
76. Pretorius AM, Jensenius M, Clarke F, Ringertz SH: Repellent efficacy of DEET and KBR 3023 against Amblyomma hebraeum (Acari: Ixodidae). J Med Entomol 40:245-248; 2003.
77. Rand PW, Lubelczyk C, Holman MS, Lacombe EH, Smith RP Jr: Abundance of Ixodes scapularis (Acari: Ixodidae) after the complete removal of deer from an isolated offshore island, endemic for Lyme disease. J Med Entomol 41:779-784; 2004.
78. Rand PW, Lacombe EH, Dearborn R, Cahill B, Elias S, Lubelczyk CB, Beckett GA, Smith RP Jr: Passive surveillance in Maine, an area emergent for tick-borne diseases. J Med Entomol 44:1118-1129; 2007.
79. Roscoe DE, Holste WC, Sorhage FE, Campbell C, Niezgoda M, Buchannan R, Diehl D, Niu HS, Rupprecht CE: Efficacy of an oral vaccinia-rabies glycoprotein recombinant vaccine in controlling epidemic raccoon rabies in New Jersey. J Wildl Dis 34:752-763; 1998.
80. Ross EA, Savage KA, Utley LJ, Tebbett IR: Insect repellent [correction of repellant] interactions: sunscreens enhance DEET (N,N-diethyl-m-toluamide) absorption. DrugMetab Dispos 32:783-785; 2004.
81. Salzman MB, Rubin LG, Sood SK: Incidence of seroconversion to Borrelia burgdorferi by immunoblot after a tcik bite in an endemic area for Lyme disease (abstract). Am J Dis Child 146:515; 1992.
82. Samish M, Ginsberg H, Glazer I: Biological control of ticks. Parasitology 129(suppl): S389-S403; 2004.
83. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM: Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 87:3768-3772; 1990.
84. Scheckelhoff MR, Telford SR, Hu LT: Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 24:1949-1957; 2006.
85. Schuijt TJ, Hovius JW, van der Poll T, van Dam AP, Fikrig E: Lyme borreliosis vaccination: The facts, the challenge, the future. Trends Parasitol 27:40-47; 2011.
86. Schwantes U, Dautel H, Jung G: Prevention of infectious tick-borne diseases in humans. Comparative studies of the repellency of different dodecanoic acid-formulations against Ixodes ricinus ticks (Acari: Ixodidae). Parasit Vectors 1:8; 2008.
87. Selim S, Hartnagel RE Jr, Osimitz TG, Gabriel KL, Schoenig GP: Absorption, metabolism, and excretion of N, N-diethyl-m-toluamide following dermal application to human volunteers. Fundam Appl Toxicol 25:95-100; 1995.
88. Shadick NA, Daltroy LH, Phillips CB, Liang US, Liang MH: Determinants of tick-avoidance behaviors in an endemic area for Lyme disease. Am J Prev Med 13:265-270; 1997.
89. Shapiro ED, Gerber MA, Holabird NB, Berg AT, Feder HM Jr, Bell GL, Rys PN, Persing DH: A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 327:1769-1773; 1992.
90. Shen AK, Mead PS, Beard CB: The Lyme disease vaccine-apublic health perspective. Clin Infect Dis 52(Suppl 3):s247-252; 2011.
91. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 339:216-222; 1998.
92. Sikand VK, Halsey N, Krause PJ, Sood SK, Geller R, van Hoecke C, Buscarino C, Parenti D: Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in healthy children and adolescents. A randomized controlled trial. Pediatrics 108:123-128; 2001.
93. Solberg VB, Miller JA, Hadfield T, Burge R, Schech JM, Pound JM: Control of Ixodes scapularis (Acari: Ixodidae) with topical self-application of permethrin by white-tailed deer inhabiting NASA, Beltsville, Maryland. J Vector Ecol 28:117-134; 2003.
94. Sood SK: Effective retrieval of Lyme disease information on the Web. Clin Infect Dis 35:451-464; 2002.
95. Sood SK, Salzman MB, Johnson BJ, Happ CM, Feig K, Carmody L, Rubin LG, Hilton E, Piesman J: Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis 175:996-999; 1997.
96. Stafford KC III: Effectiveness of carbaryl applications for the control of Ixodes dammini (Acari: Ixodidae) nymphs in an endemic residential area. J Med Entomol 28:32-36; 1991.
97. Stafford KC III: Tick Management Handbook. New Haven, The Connecticut Agricultural Experiment Station; 2007.
98. Stanek G, Kahl O: Chemoprophylaxis for Lyme borreliosis? ZentralblBakteriol 289:655-665; 1999.
99. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339:209-215; 1998.
100. Steere AC, Drouin EE, Glickstein LJ: Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 52 (Suppl 3):s259-265; 2011.
101. Tenenbein M: Severe toxic reactions and death following the ingestion of diethyltoluamide-containing insect repellents. JAMA 258:1509-1511; 1987.
102. Thanassi WT, Schoen RT: Successful vaccination for Lyme disease. A novel mechanism. Expert Opin Investig Drugs 8:29-35; 1999.
103. Tsao JI, Wootton JT, Bunikis J, Luna MG, Fish D, Barbour AG: An ecological approach to preventing human infection. Vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle. Proc Natl Acad Sci USA 101:18159-18164; 2004.
104. Vazquez M, Muehlenbein C, Cartter M, Hayes EB, Ertels S, Shapiro ED: Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis 14:210-216; 2008.
105. Veltri JC, Osimitz TG, Bradford DC, Page BC: Retrospective analysis of calls to poison control centers resulting from exposure to the insect repellent N,N-diethyl-m-toluamide (DEET) from 1985-1989. J Toxicol Clin Toxicol 32:1-16; 1994.
106. Wikel SK: Host immunity to ticks. Annu Rev Entomol 41:1-22; 1996.
107. Wikel SK, Ramachandra RN, Bergman DK, Burkot TR, Piesman J: Infestation with pathogen-free nymphs of the tick Ixodes scapularis induces host resistance to transmission of Borrelia burgdorferi by ticks. Infect Immun 65:335-338; 1997.